Celldex Therapeutics completed enrollment six months ahead of schedule in its Phase 3 trials for barzolvolimab, a promising treatment for chronic spontaneous urticaria, with topline data expected in Q4 2026 and a planned Biologics License Application (BLA) submission in 2027. The company also continues enrolling patients in Phase 3 studies for cold urticaria and symptomatic dermographism, while advancing other pipeline candidates like CDX-622. Celldex strengthened its financial position by raising $345 million in a public offering in April 2026, supporting ongoing research and commercialization efforts. The company expects multiple key data readouts across its pipeline throughout 2026, aiming to transform treatment options for allergic and inflammatory diseases.
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
